ストックスクリーナーアプリを入手
45.95
2.45%
1.10
アフターアワーズ：
45.88
-0.07
-0.15%
Livanova Plc (LIVN) 最新ニュース
LivaNova completes epilepsy treatment study of VNS Therapy - Medical Device Network
VNS therapy shows sustained seizure reduction in study By Investing.com - Investing.com South Africa
LivaNova Announces CORE-VNS 24-Month Data Show Adjunctive VNS Therapy is Associated with Substantial Reductions in Generalized Tonic-Clonic Seizures in People with Drug-Resistant Epilepsy - BioSpace
LivaNova at Jefferies Conference: Strategic Growth and Challenges - Investing.com
LivaNova at Jefferies Conference: Strategic Growth and Challenges By Investing.com - Investing.com UK
Artificial Heart Lung Machines Market Projected to Witness - openPR.com
LIVN Reports Promising Outcomes in Drug-Resistant Epilepsy Study - GuruFocus
LIVN Reports Promising Outcomes in Drug-Resistant Epilepsy Study | LIVN Stock News - GuruFocus
LivaNova reports positive VNS Therapy study results for epilepsy - Investing.com
CORE-VNS Study Further Validates Effectiveness of LivaNova's VNS Therapy on Severe Focal Seizures in Both Children and Adults with Drug-Resistant Epilepsy | LIVN Stock News - GuruFocus
LivaNova reports positive VNS Therapy study results for epilepsy By Investing.com - Investing.com UK
LivaNova Announces CORE-VNS 24-Month Data Show Adjunctive VNS Therapy is Associated with Substantial Reductions in Generalized Tonic-Clonic Seizures in People with Drug-Resistant Epilepsy | LIVN Stock - GuruFocus
LivaNova plc (LIVN) completes CORE-VNS study - StreetInsider
VNS therapy shows sustained seizure reduction in study - Investing.com
CORE-VNS Study Further Validates Effectiveness of LivaNova’s VNS Therapy on Severe Focal Seizures in Both Children and Adults with Drug-Resistant Epilepsy - The Joplin Globe
LivaNova (LIVN) Announces CORE-VNS 24-Month Data Show Adjunctive VNS Therapy is Associated with Substantial Reductions in Generalized Tonic-Clonic Seizures in People with Drug-Resistant Epilepsy - StreetInsider
LivaNova seeks Medicare coverage reconsideration for VNS Therapy By Investing.com - Investing.com South Africa
LivaNova wants CMS to reconsider neuromod for treating depression - MassDevice
Bioelectronic Medicine Market Research Report 2025 Featuring Key PlayersMedtronic, Abbott, Boston Scientific, Cochlear, LivaNova, Soterix Medical, Bioinduction, GiMer Medical, CEFALY, BioControl - GlobeNewswire
LivaNova Seeks Reconsideration of National Medicare Coverage for VNS Depression Treatment - marketscreener.com
LivaNova Initiates Process with U.S. Centers for Medicare and Medicaid Services for Reconsideration of National Coverage for VNS Therapy for Treatment-Resistant Depression - marketscreener.com
LivaNova Initiates Process with U.S. Centers for Medicare and Me - GuruFocus
LivaNova (LIVN) Seeks Expanded Medicare Coverage for VNS Therapy | LIVN Stock News - GuruFocus
LivaNova seeks Medicare coverage reconsideration for VNS Therapy - Investing.com India
LivaNova (LIVN) Initiates Process with U.S. Centers for Medicare and Medicaid Services for Reconsideration of National Coverage for VNS Therapy for Treatment-Resistant Depression - StreetInsider
LivaNova Announces 12-month Data from OSPREY Study - Medical Product Outsourcing
Vagus Nerve Stimulation (VNS) Market Poised for Breakthrough Growth: From $488.5M in 2022 to $836.1M by 2032 - openPR.com
LivaNova PLC (NASDAQ:LIVN) Receives Average Recommendation of “Buy” from Analysts - Defense World
Electroceuticals Market Generated Opportunities, Future - openPR.com
LivaNova’s SWOT analysis: medical device firm’s stock faces growth hurdles By Investing.com - Investing.com India
LivaNova’s SWOT analysis: medical device firm’s stock faces growth hurdles - Investing.com Australia
LivaNova's SWOT analysis: medical device firm's stock faces growth hurdles - Investing.com
(LIVN) Technical Data - news.stocktradersdaily.com
LivaNova PLC (NASDAQ:LIVN) Shares Acquired by Deutsche Bank AG - Defense World
LivaNova faces $360M liability after court ruling By Investing.com - Investing.com South Africa
LivaNova faces $360M liability after court ruling - Investing.com India
LivaNova (NASDAQ:LIVN) Raised to Outperform at Wolfe Research - Defense World
LivaNova Faces Legal Dispute Over Environmental Liabilities - TipRanks
Wolfe Research Upgrades LivaNova (LIVN) - Nasdaq
LivaNova (LIVN) Receives Upgrade to "Outperform" by Wolfe Research | LIVN Stock News - GuruFocus
Wolfe Research lifts Livanova stock rating, sets $60 target By Investing.com - Investing.com Nigeria
LivaNova (LIVN) Upgraded by Wolfe Research with a Positive Outlo - GuruFocus
LivaNova (LIVN) Upgraded by Wolfe Research with a Positive Outlook | LIVN Stock News - GuruFocus
LivaNova (LIVN) Receives Upgrade to "Outperform" by Wolfe Resear - GuruFocus
Bank of America Corp DE Sells 94,006 Shares of LivaNova PLC (NASDAQ:LIVN) - Defense World
LivaNova PLC (NASDAQ:LIVN) Shares Bought by BNP Paribas Financial Markets - Defense World
Combined Companies Sorin and Cyberonics Will Be Renamed LivaNova - Medical Product Outsourcing
LivaNova to Present at the Jefferies Global Healthcare Conference - The Joplin Globe
LIVN Stock Rating Reiterated at 'Buy' by Needham Analyst | LIVN - GuruFocus
LivaNova PLC (NASDAQ:LIVN) Q1 2025 Earnings Call Transcript - Insider Monkey
How to Take Advantage of moves in (LIVN) - news.stocktradersdaily.com
LivaNova PLC: Strong Growth Amidst Challenges in Earnings Call - TipRanks
Electroceuticals Market Top PlayersMedtronic Plc (Ireland), - openPR.com
0.56%
1.70%
大文字化:
|
ボリューム (24 時間):